Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
Sponsor: Dr Cipto Mangunkusumo General Hospital
A PHASE2 clinical study on Graves Disease, this trial is completed. The trial is conducted by Dr Cipto Mangunkusumo General Hospital and has accumulated 9 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Mar 2020 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dr Cipto Mangunkusumo General Hospital
- Indonesia University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.